Kawada and T.C. Walser similarly pointed out CXCL9 and/or CXCR3 antagonism meant better prognosis in melanoma and breast cancers, it also can inhibited the cancer metastasis[28,29].Zheng Jiang et al indicated that the expression of CXCL10 was an important prognosticator in stage II and III CRC, and it was relevant to CRC patients’ survival [30]. The gene discussed is CXCL9; the disease is breast carcinoma.